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Abstract
Background: Irritable bowel syndrome (IBS) is highly prevalent worldwide but
mechanisms for healthcare seeking behaviours in this patient group are poorly
understood.
Objective: To describe healthcare utilization and identify factors associated with
seeking healthcare amongst IBS subjects in the general population.
Methods: An internet survey was completed by 6,300 individuals equally distrib-
uted between United States, United Kingdom and Canada. The Rome IV diagnostic
questionnaire was used to identify subjects with IBS. Data on demographics, med-
ical history, gastrointestinal (GI) and non‐GI symptoms, quality of life and health
care consumption was collected.
Results: A total of 5,931 subjects were included; 274 (4.6%) IBS subjects and 5657
(95.3%) non‐IBS controls. IBS subjects reportedmore doctor consultations for bothGI
and other health problems as well as increased use of medication and rate of
abdominal surgery (appendectomy excluded). Having healthcare insurance or access
to free public healthcare (adjusted odds ratio (AOR) 4.49, 95%confidence interval (CI)
1.31–15.44), followed by high frequency of bloating (AOR 2.65, 95% CI 1.42–4.93)
and increasing age (AOR 1.02, 95% CI 1.01–1.05) were found to be independently
associated with being an IBS consulter while doctor‐diagnosed IBS subjects were
more likely to be female and to report abdominal pain as their most bothersome GI
symptom than other consulters with IBS.
Conclusion: IBS subjects have higher healthcare utilization than non‐IBS controls,
medication use and abdominal surgery included. Furthermore, consulters with and
without an IBS diagnosis differ in sex distribution and symptom profiles. Hence,
awareness of the possibility of unnecessary medical and surgical treatment in IBS
subjects and a sex‐related diagnostic bias by doctors is warranted.
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Irritable bowel syndrome (IBS) is one of the most prevalent func-
tional gastrointestinal (GI) disorders,1 characterized by chronic or
recurrent abdominal pain associated with altered bowel habits.2 It is
also associated with impaired quality of life,3 decreased work pro-
ductivity4 and increased health and socioeconomic costs.3,5 Many
doctors find the disorder challenging to manage6 and likewise many
IBS patients are dissatisfied with the management, often leading to
frequent healthcare visits.7 This partly explains why IBS is one of the
most common reasons for gastroenterological consultations in both
primary and secondary care.8
Understanding the mechanisms for healthcare seeking behaviour
is essential in order to identify patients' needs and to optimize
management. Factors such as GI symptom severity, psychological
distress, psychosocial factors and extra‐intestinal symptom burden
are considered as important contributors to healthcare seeking in the
IBS population. In a US community survey, abdominal pain was the
most common reason for consulting a doctor, but as many as 75% of
those with IBS symptoms never consulted doctors about their GI
problems.9 Similar findings have been reported by others, that is GI
symptom severity is of importance, but does not entirely explain
healthcare seeking behaviour.10–12 IBS consulters have also been
found to suffer from increased psychological distress compared to
both non‐consulting IBS subjects and non‐IBS controls.13,14 However,
as previous studies have used earlier versions of the IBS criteria,
assessed specific IBS subtypes or small or selected samples, their
generalizability is limited.9,10,15 Furthermore, it can be assumed that
healthcare seeking behaviour in general have changed over time and
also differs between countries and healthcare systems. Hence,
healthcare consumption and mechanisms of healthcare seeking
behaviour in the IBS population is still poorly understood and
updated knowledge is needed.
To address this issue, we used a large population‐based sample
from three English‐speaking countries16 in order to identify IBS
subjects according to the Rome IV criteria with the aims of (1)
describing healthcare utilization in the IBS population compared to
non‐IBS controls, and to (2) identify factors associated with health-
care seeking amongst IBS subjects.
METHODS
Study design and data collection
Representative nationwide general population samples in the United
States (US), Canada and United Kingdom (UK) were identified by a
global market survey company, Qualtrics Inc. (Provo, Utah, United
States). Quota‐based sampling was used to achieve pre‐defined and
comparable distributions in all three countries in regard to sex
(50%:50%), age (40% aged 19–39 years, 40% aged 40–64 years, and
20% aged >65 years) and education level (≤30% with >16 years of
formal education). The sample size was based on the intention to
capture 100–200 cases per country of the main functional GI disor-
ders calculated by an estimated prevalence of 5%‐10% per diagnosis.
Eligible participants were invited to complete an online survey on
general health, with no mention of the GI context. Participants
received points from Qualtrics Inc. that could be exchanged for
shopping credits, but no monetary compensation or gift was issued. A
personal invitation was needed to access the survey and the regis-
tered participants could only complete the survey once. Automated
skip patterns and several quality assurance mechanisms were used to
minimize poor data quality. Participants were required to complete
each applicable question in order to move forward in the question-
naire. Participants who failed to respond consistently on at least two
of three pairs of identical questions on GI symptoms presented twice
in different parts of the survey were classified as inconsistent re-
sponders, and their data were not included in the data analysis.
Further details of the survey methodology can be found
elsewhere.16
Questionnaires
The survey consisted of
‐ The validated Rome IV diagnostic questionnaire17 used to identify
IBS subjects and GI symptom burden.
‐ Demographic questions: age, sex, ethnicity, relationship status and
home district.
‐ The Physical Health Questionnaire (PHQ)‐12 18 used to determine
presence, severity and number of extra‐intestinal symptoms.
‐ The Short Form (SF)‐8 questionnaire19 used to assess health‐
related quality of life.
Key summary
Summarise the established knowledge on this subject
� Irritable bowel syndrome (IBS) is associated with
impaired functioning in both work and personal activities
� IBS is associated with high healthcare use and costs
What are the significant and/or new findings of this study?
� Updated knowledge regarding the extent of healthcare
utilization and associated demographics in a general IBS
population defined by the Rome IV criteria
� Bloating, increasing age and having healthcare insurance
or access to free public healthcare are independently
associatedwithhealthcareutilization in the IBSpopulation
� It is more common for female IBS consulters with
abdominal pain as a prominent symptom to receive a
formal IBS diagnosis
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‐ Medical history, healthcare utilization and other healthcare related
questions enquiring for:
‐ Doctor‐diagnosed GI diseases, including celiac disease, inflam-
matory bowel disease, peptic ulcer, diverticulitis, GI cancer and
functional GI disorders including IBS.
‐ Doctor visits, including type of specialist seen, related to po-
tential GI problems.
‐ Doctor visits related to any health problem.
‐ History of abdominal surgeries, including cholecystectomy,
hysterectomy, appendectomy, bowel resection and other pelvic
or abdominal surgeries.
‐ Regular (≥once/week) use of medications for constipation,
diarrhoea, nausea, heartburn or to reduce stomach acid, pain
(prescribed or over the counter but without any specification of
the type of pain treated), gas or bloating, anxiety or depression.
‐ Healthcare insurance status.
Definitions
IBS subjects and non‐IBS controls
IBS subjects: Participants fulfilling Rome IV criteria for IBS2 without
self‐reported history of doctor‐diagnosed organic GI diseases or
history of bowel resection. The excluded organic diseases were
decided a priori and included inflammatory bowel disease, celiac
disease, GI cancer, peptic ulcer and diverticulitis.
Non‐IBS controls: all remaining subjects, including those meeting
Rome IV criteria for other functional GI disorders than IBS, and those
with organic GI disease even if fulfilling Rome IV criteria for IBS.
IBS consulters and IBS non‐consulters
IBS consulters: IBS subjects reporting having consulted a doctor for a
GI problem.
IBS non‐consulters: IBS subjects without history of doctor
consultation for a GI problem.
Diagnosed and undiagnosed IBS consulters
Diagnosed IBS consulters: IBS consulters reporting having been
diagnosed with IBS by a doctor.
Undiagnosed IBS consulters: IBS consulters, without information
about being diagnosed with IBS by a doctor.
See Figure 1 for overview of the study cohort and subgroups.
Statistical analyses
IBM SPSS Statistics version 22.0 (SPSS Inc. Chicago) was used for
statistical analysis. Due to the survey methodology, there were no
missing data. Statistical significance was set at a p‐value <0.05, all
confidence intervals (CI) were 95%.
Demographics, symptom burden and overall healthcare utiliza-
tion was compared between IBS subjects and non‐IBS controls, IBS
consulters and IBS non‐consulters as well as between diagnosed and
undiagnosed IBS consulters. Chi‐square test was used to compare
categorical variables, and results presented as absolute numbers
and percent. To meet test criteria and ensure relevant group com-
parisons, dichotomized groups were created as follows; population
size where the subjects live defined by either more or less than
50,000 inhabitants, relationship status as “In a relationship” or “Not
in a relationship”, frequency of bloating as <3 times/month or ≥3
times/month, frequency of abdominal pain as <3 times/week or ≥3
times/week, frequency of doctor visits as ≤1 visit/year or >1 visit/
year, and having healthcare insurance or access to free public health
care as “yes” or “no”. Continuous variables were analysed with
Students T‐tests and presented as mean values along with standard
deviations.
Logistic regression analysis was performed to identify factors
independently associated with being an IBS consulter versus IBS
non‐consulter. Variables included in the regression analysis were
either decided prior to data analysis based on empirical assumptions
or statistical significance in the univariate analysis. Among them,
health insurance status was included as it differs in the three
countries and is expected to impact consulting behavior, and the
mental component score of SF‐8 as this is the only variable that can
be used to assess the potential impact of psychiatric distress on
consulting behavior. Multicollinearity can cause unstable coefficient
estimates which leads to inaccurate odds ratios of predictor vari-
ables. In the current analysis, all predictor variables were found to
have low (<3) variance inflation factor, indicating that multi-
collinearity was not of concern.
Results from the logistic regression analysis are presented as





















F I GUR E 1 Schematic overview of the study cohort and the
IBS subgroups used for comparisons. A total of 4.6% of the
cohort fulfilled Rome IV criteria for IBS (IBS subjects) and a
majority of them reported having consulted a doctor for a
gastrointestinal problem (IBS consulter). Of the IBS consulters,
55% had also been diagnosed with IBS by a doctor (Diagnosed
IBS consulters)
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Ethics
The Institutional Review Board at the University of North Carolina,
United States reviewed the study, and decided that ethical approval
was not needed as the survey was anonymous.
RESULTS
General characteristics of the cohort
A total of 6,300 subjects were recruited for participation, 2,100 from
each country. Of these, 369 (5.9%) were identified as inconsistent
responders leaving 5,931 subjects, equally distributed across US,
Canada and UK, for analysis. The mean age of the entire cohort was
47.4 (17.1) years; 2,918 (49.2%) were females and 4,244 (71.5%) of
white race. See Figure 1 and Table 1.
Characteristics of the IBS cohort
General characteristics
A total of 274 (4.6%) subjects in the sample were classified as IBS
subjects after excluding 67 individuals that reported organic GI dis-
ease or history of bowel resection. The remaining 5,657 (95.3%)
subjects were classified as non‐IBS controls. Of the IBS subjects, 168
(61.3%) were identified as IBS consulters and of those 92 (54.8%)
were classified as diagnosed IBS consulters. The proportion of diag-
nosed IBS consulters was larger in the UK compared to the other
countries, but the proportion of IBS subjects and IBS consulters was
similar across all three countries. See Figure 1 and Table 1 for an
overview of the study cohort.
Demographics
IBS subjects were younger and predominantly female compared to
the non‐IBS controls. IBS consulters were older than IBS non‐
consulters, but diagnosed and undiagnosed IBS consulters were of
similar age. IBS consulters and IBS non‐consulters had similar sex
distribution, whereas diagnosed IBS consulters had greater female
predominance compared to undiagnosed IBS consulters. Being an
undiagnosed IBS consulter was most common in the USA and least
common in the UK. Ethnicity and IBS subtype was similar across all
comparisons. See Table 1 for details.
Gastrointestinal and non‐gastrointestinal symptom
burden
IBS subjects more frequently rated abdominal pain as their most
bothersome GI symptom and had significantly more frequent GI
symptoms than non‐IBS controls. IBS subjects also had an excess of
non‐GI symptoms, as seen in both the sum scores and the absolute
number of somatic symptoms on the PHQ‐12 questionnaire
(Table 2).
IBS consulters reported frequent bloating more commonly than
IBS non‐consulters, but presence or frequency of abdominal pain was
not found to be related to consultation status, nor was non‐GI
symptom burden. Finally, diagnosed IBS consulters more commonly
rated abdominal pain as their most bothersome symptom, whereas
frequency of abdominal pain or bloating and number of non‐GI
symptoms did not differ from undiagnosed consulters. See
Figures 2 and 3 for details on GI symptom burden and Table 2 for
non‐GI symptom burden.
Health‐related quality of life
The general health‐related quality of life on the SF‐8 was impaired in
IBS subjects compared to non‐IBS controls. IBS consulters had lower
physical quality of life scores than IBS non‐consulters, while the
mental quality of life scores did not differ between those groups.
Diagnosed IBS consulters reported better mental quality of life than
undiagnosed consulters, but similar overall and physical quality of
life. Table 2 summarizes all measures of health‐related quality of life.
Healthcare utilization
Compared to non‐IBS controls, IBS subjects more commonly re-
ported having consulted a doctor for a GI problem, and also reported
visiting doctors more frequently for any reason. Consultations about
GI problems were most commonly with general practitioners/family
doctors or gastroenterologists. The overall rate of abdominal surgery
and medication utilization was greater among IBS subjects compared
to non‐IBS controls; all types of abdominal surgery that was surveyed
except for appendectomy were more prevalent in IBS subjects, as
was the use of analgesics, GI‐relevant medications and psychotropics
(Table 3).
IBS consulters and IBS non‐consulters reported similar fre-
quency of doctor visits for any health reason. They also reported
similar rates of cholecystectomy, appendectomy and unspecified
pelvic or abdominal surgery, as well as utilization of anxiolytics, anti‐
depressants and over the counter analgesics. However, the overall
rate of abdominal surgery was increased among IBS consulters, which
was mainly due to the significantly higher rate of hysterectomy
compared to IBS non‐consulters. Furthermore, IBS consulters more
commonly reported regular use of medications for constipation,
diarrhoea, acid suppression and gas/bloating, and increased use of
prescribed analgesics and antidepressants, compared to IBS non‐
consulters. Diagnosed and undiagnosed IBS consulters reported
similar frequency of overall doctor visits and abdominal surgeries, as
well as of all types of medications used regularly. See Table 3 for
details on health care consumption.
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Factors associated with consulting behaviour in IBS
subjects
In a logistic regression analysis aimed at identifying factors indepen-
dently associated with consulting for IBS, the following variables were
included in the model: age, gender, country, healthcare insurance
status, ethnicity, relationship status, most bothersome GI symptom,
frequency of abdominal bloating, frequency of abdominal pain, IBS
subtype, PHQ‐12 score and SF‐8 mental component score. We found
that the strongest independent predictor for being an IBS consulter
was having healthcare insurance or access to free public healthcare,
followed by high frequency of bloating and increasing age (Table 4).
Discussion
In this study we have characterized healthcare utilization and iden-
tified factors of importance for seeking healthcare among subjects















Total 274 (4.6) 5657 (94.5) 168 (61.3) 106 (38.7) 92 (54.8) 76 (45.2)
Mean age (SD) 43.5 (14.2) 47.6 (17.2) p < 0.001 45.7 (14.3) 40.1 (13.2) p < 0.001 45.5 (14.5) 46 (14) 0.79
Female n (%) 177 (64.6) 2741 (48.5) p < 0.001 104 (61.9) 73 (68.9) 0.24 64 (69.5) 40 (52.6) 0.02
Country, n (%) 0.95 0.82 0.01
USA 92 (4.7) 1857 (95.3) 55 (59.8) 37 (40.2) 23 (25) 32 (35.8)
Canada 90 (4.5) 1898 (95.5) 57 (63.3) 33 (36.7) 30 (33.3) 27 (30)






111 (40.5) 2518 (44.5) 68 (40.5) 43 (40.6) 32 (34.8) 36 (47.4)
Married or
cohabiting
163 (59.5) 2139 (55.5) 100 (59.5) 63 (59.4) 60 (65.2) 40 (52.6)
Home district, n (%) 0.51 0.70 0.50
Urban (>50. 000
inhabitants)
141 (51.1) 3026 (53.5) 88 (52.4) 53 (50) 46 (50) 34 (44.7)
(<50.000
inhabitants)
133 (48.5) 2631 (46.5) 80 (47.6) 53 (50) 46 (50) 42 (55.3)
Ethnicity, n (%) 0.07 0.46 0.27
White/caucasian 197 (71.9) 4074 (72) 121 (72) 76 (71.7) 69 (75) 52 (68.4)
Non white/
caucasian
42 (15.3) 1063 (18.7) 23 (13.7) 19 (17.9) 9 (9.8) 14 (18.4)
Not disclosed 35 (12.8) 520 (9.2) 24 (14.3) 11 (10.4) 14 (15.2) 10 (13.2)
IBS subtype, n (%) 0.11 0.34
IBS‐C 78 (28.5) N/A 46 (27.4) 32 (30.2) 24 (26.1) 22 (28.9)
IBS‐D 96 (35) N/A 61 (36.3) 35 (33) 33 (35.9) 28 (36.8)
IBS‐M 85 (31) N/A 56 (33.3) 29 (27.4) 34 (37) 22 (28.9)
IBS‐U 15 (5.5) N/A 5 (3) 10 (9.4) 1 (1) 4 (5.3)
At least partial health care benefits n (%)
USA 77 (83.7) 1643 (88.5) 0.17 51 (92.7) 26 (70.3) 0.004 21 (91.3) 30 (93.8) 0.73
Canada 89 (98.9) 1842 (97) 0.31 56 (98.2) 33 (100) 0.44 29 (96.7) 27 (100) 0.34
UK 92 (100) 1862 (97.9) 0.16 56 (100) 36 (100) N/A 39 (100) 17 (100) N/A
Note: Significant differences in bold.
Abbreviation: IBS, irritable bowel syndrome.
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with IBS in a general population cohort. IBS was associated with
increased healthcare utilization, and the majority of IBS subjects had
consulted a physician for GI‐related problems. However, healthcare
utilization in IBS consulters and IBS non‐consulters were similar for
health problems in general. Having healthcare insurance or free
public healthcare, more frequent bloating and increasing age were
independently associated with healthcare seeking among IBS
subjects.
Our report of 61% of IBS subjects having had a doctor appoint-
ment due to a GI problem is within the range previously reported
based on other IBS definitions.9–11 Two of our findings regarding IBS
consulters contradict common clinical perception; we found that IBS
consulters were older compared to IBS non‐consulters and that no
relative female predominance was present amongst IBS consulters.
Interestingly, the relative female predominance reappeared in the
subset of consulters who had received a clinical IBS diagnosis
compared to the undiagnosed IBS consulters. This has not been re-
ported before and might indicate a sex‐dependent discrepancy in
physicians' diagnosis of IBS. Furthermore, diagnosed IBS consulters
more commonly reported abdominal pain as the most bothersome
symptom, while neither presence nor frequency of abdominal pain
were found to be associated to consulting behaviour amongst IBS
subjects. These findings suggest that doctors are more likely to di-
agnose IBS if abdominal pain is prominent in the symptom presenta-
tion. By considering these discrepancies regarding the risk for IBS
consulters of male sex and those where bloating is most bothersome
to not receive an IBS diagnosis, doctors might improve their diagnostic
accuracy and adapt treatment for IBS patients more effectively.



















Total n (%) 274 (4.6) 5657 (94.5) 168 (51.3) 106 (38,7) 92 (54.8) 76 (45.2)
PHQ‐12 mean (SD)
Score 9.7 (4.4) 4.5 (3.6) <0.001 9.7 (4.4) 9.6 (4.3) 0.78 9.3 (4.3) 10.3 (4.5) 0.17
No of somatic
symptoms, T‐test.
3 (2.3) 0.9 (1.4) <0.001 3 (2.3) 2.9 (2.3) 0.82 2.8 (2.3) 3.2 (2.4) 0.32
SF‐8 mean (SD)
PCS 39 (11) 50 (9) <0.001 38 (11) 41 (11) 0.02 38 (11) 38 (11) 0.65
MCS 39 (12) 50 (11) <0.001 39 (11) 37 (13) 0.16 41 (11) 38 (10) 0.04
Total SF‐score 234 (85) 393 (49) <0.001 320 (56) 326 (60) 0.44 326 (60) 314 (52) 0.14
Note: Significant differences in bold.
Abbreviations: IBS, irritable bowel syndrome; MCS, Mental component score; PCS, Physical component score; PHQ‐12, Patient Health Questionnaire‐
12 (Extra‐intestinal symptoms); SF‐8, Short Form‐8 (Health Related Quality of Life).
IBS subjects
Abdominal pain Loose stools or high frequency of stools Hard stools or low frequency of stools
Bloating None of the above











F I GUR E 2 Bar charts displaying the most bothersome gastrointestinal symptom in all groups
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IBS subjects in our sample had poorer quality of life compared
to non‐IBS controls, which has been repeatedly shown.3,20,21 Inter-
estingly, we found that IBS consulters scored lower on the physical,
but not mental, quality of life components compared with the IBS
non‐consulters. This is in conflict with results from previous studies
suggesting psychological distress to be an important factor for
healthcare consumption.11,13,14,22 However, a major limitation with
the cross‐sectional design of our study is that it does not allow for
causation analysis and cannot assess the potential bias introduced
by the impact of consultations or treatments. Receiving a diagnosis,
structured information, diet advice and treatment with medications,
might have changed symptoms in the IBS‐consulters group23 in a
way that our study cannot correct for, for example reduced the
impact of abdominal pain or other GI symptoms asked for by the
survey.
Our study clearly shows that fulfilling diagnostic criteria for IBS
is associated with increased utilization of medications. This is ex-
pected for medications aiming at relieving IBS symptoms based on
treatment recommendations, such as constipation and diarrhoea.6
The increased use of antidepressants and anxiolytics are also ex-
pected, both as treatment of IBS,24 and for comorbid depression and
anxiety,25 while the increased use of antiemetics and acid‐
suppressive medications may partly be explained by the significant
overlap with other functional GI disorders in this population.16
Added to this, self‐medication is not uncommon in IBS and
dyspepsia.26 The increased use of medication for bloating in the IBS
consulter group probably reflects how common and bothersome this
symptom is. As high frequency of bloating is also associated with
being an IBS consulter, we believe that bloating needs to be actively
addressed in subjects with IBS,27 even though it is not a part of the
Rome IV diagnostic criteria for the disorder.28 Moreover, the excess
use of analgesics in IBS subjects is worrying, particularly as it was
more pronounced in the IBS consulters group. This finding can
partly be explained by pain related to comorbid diagnoses associ-
ated with IBS,29 such as fibromyalgia and endometriosis.30 Another
possible explanation is that the increased use of analgesics could be
a result of doctors' frustration in treating abdominal pain in IBS,31 or
unsatisfactory knowledge of other, more effective treatments. This
indicates a need for educational efforts regarding effective phar-
macologic and non‐pharmacologic treatment options for IBS‐related
pain.6,32
The rate of abdominal surgical interventions in the IBS popu-
lation was almost double that of the non‐IBS controls. This has
been reported previously33–35 and theories proposed in the past to
explain this excess of surgeries in IBS have included misdiagnosis
and post‐operative IBS,33–35 explanations that a cross‐sectional
study design is unable to prove. The increase in hysterectomies
that we found in the IBS population can be expected and probably
reflects the higher female prevalence in IBS, and the similar rates
of appendectomies in the IBS subjects and non‐IBS controls might
reflect a greater awareness amongst physicians and better trust in
non‐invasive diagnostic tools in this specific surgical area. How-
ever, the increased rate of cholecystectomies in the younger IBS
population, compared to non‐IBS controls, is considered to be
relevant as increasing age otherwise is a risk factor for this sur-
gical intervention. Still, our results highlight a need for continued
awareness of this issue in order to avoid unnecessary surgical
interventions in IBS.
A key strength of our study is that it was conducted with a
validated methodology in a large, representative, population‐based
sample.16 Moreover, survey participants were not aware of the GI
focus of the survey when they consented to participate, minimizing
the risk of inclusion bias. Built‐in data quality assurance mechanisms
further reduced the risk for poor data and eliminated the problem of
missing data. All of these factors contribute to the generalizability of
our results. Our findings that subjects fulfilling Rome IV criteria for
IBS were predominantly female and of younger age,2 that they suf-
fered from both excess GI and non‐GI symptoms18 and had a high
burden of non‐GI symptoms, all support the position that we have
indeed identified a relevant IBS population. As such, we believe that
our study presents a novel, comprehensive and accurate analysis of
healthcare utilization and factors driving health care seeking
behaviour in IBS.
Nevertheless, our study has limitations. First, the Rome IV
diagnostic questionnaire was not translated to all languages used by
citizens of the three countries at the time of this study, limiting us
to the English‐speaking populations. This means, for example, that
some native French‐speaking people in Canada were unable to
participate. Second, about one third of subjects fulfilling criteria for
45























































F I GUR E 3 (a) Bar chart showing abdominal pain more than 3
times/week. (b) Percent of IBS subjects with abdominal bloating
more than 3 times/month
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Total n (%) 274 (4.6) 5657 (94.5) 168 (51.3) 106 (38,7) 92 (54.8) 76 (45.2)
Ever visited any doctor for bowel related problems 168 (61.3) 1203 (21.3) <0.001 168 (100) ‐ N/A 92 (100) 76 (100) N/A
Frequency of general doctor visits
≥1 visit per year 213 (77.7) 3194 (56.5) <0.001 134 (79.8) 79 (74.5) 0.31 77 (83.7) 57 (75) 0.16
Specialist consultations for GI problems, n (%)
General practitioner/family doctor 153 (55.8) 1081 (19.1) <0.001 153 (91.1) ‐ N/A 85 (92.4) 68 (89.5) 0.51
Gastroenterologist 84 (30.7) 488 (8.6) <0.001 84 (50) ‐ N/A 49 (53.3) 35 (46.1) 0.35
Gynecologist 15 (5.5) 74 (1.3) <0.001 15 (0.09) ‐ N/A 11 (12) 4 (5.3) 0.13
Surgeon 20 (7.3) 157 (2.8) <0.001 20 (11.9) ‐ N/A 10 (10.9) 10 (13.2) 0.65
Abdominal surgery, n (%)
Cholecystectomy 41 (15) 430 (7.6) <0.001 29 (17.3) 13 (12.3) 0.26 16 (17.4) 13 (17.1) 0.96
Appendectomy 30 (10.9) 573 (10.1) 0.66 22 (13.1) 8 (7.5) 0.15 12 (14.1) 9 (11.8) 0.66
Hysterectomy 26 (9.5) 346 (6.1) 0.03 21 (12.5) 5 (4.7) 0.03 11 (12) 10 (13.2) 0.81
Other (unspecified) abdominal or pelvic surgery 45 (16.4) 415 (7.3) <0.001 33 (19.6) 12 (11.3) 0.07 21 (22.8) 12 (15.8) 0.25
At least one of the above 112 (40.9) 1337 (23.6) <0.001 79 (47) 33 (31.1) <0.001 49 (53.3) 30 (39.5) 0.08
Regular drug use, n (%)
Medication for constipation 65 (23.7) 296 (5.2) <0.001 55 (32.7) 10 (9.4) <0.001 35 (38) 20 (26.3) 0.11
Medication for diarrhea 56 (20.4) 178 (3.2) <0.001 49 (29.2) 7 (6.6) <0.001 30 (32.6) 19 (25) 0.28
Medication for nausea 47 (17.2) 158 (2.8) <0.001 33 (19.6) 14 (13.2) 0.17 18 (19.6) 15 (19.7) 0.98
Medication for heartburn or stomach acid 135 (49.3) 1020 (18) <0.001 96 (57.1) 39 (36.8) <0.001 52 (56.5) 44 (57.9) 0.86
Medication for pain, prescribed 105 (38.3) 809 (14.3) <0.001 77 (45.8) 28 (26.4) <0.001 45 (48.9) 32 (42.1) 0.38
Medication for pain, not prescribed 104 (38) 998 (17.6) <0.001 61 (36.3) 43 (40.6) 0.48 32 (34.8) 29 (38.2) 0.65
Medication for gas/bloating 60 (21.9) 266 (4.7) <0.001 49 (29.2) 11 (10.4) <0.001 30 (32.6) 19 (25) 0.28
Medication for anxiety 83 (30.3) 586 (10.4) <0.001 58 (34.5) 25 (23.6) 0.06 34 (37) 24 (31.6) 0.47
Medication for depression 97 (35.4) 696 (12.3) <0.001 68 (40.5) 29 (27.4) 0.03 37 (40.2) 31 (40.8) 0.94
GI‐related medication (constipation, diarrhea, acid, gas/
bloating)
171 (62.4) 1307 (23.1) <0.001 124 (73.8) 47 (44.3) <0.001 25 (27.2) 19 (25) 0.75
Note: Significant differences in bold.






































IBS reported that they had never seen a doctor for their GI health
issues, meaning that their GI symptoms had not been clinically
evaluated for possible alternative causes. Additionally, healthcare
insurance systems vary from country to country, and Canada and
the UK are supposed to have universal healthcare. Hence, health
insurance status was included in the logistic regression analysis and
its expected impact of insurance status on consulting behavior was
confirmed.
In summary, IBS subjects have increased healthcare utilization,
are more likely to use medications regularly, and undergo abdominal
surgeries more frequently than other people. IBS consulters are more
likely to be older and have increased frequency of bloating than other
people with IBS, whilst IBS consulters that have also been formally
diagnosed with IBS are predominantly female and more bothered by
abdominal pain. Based on these findings, we suggest that greater
clinical awareness is warranted regarding potentially unnecessary
medical and surgical treatment in IBS subjects, as well as regarding
possible sex‐dependent bias in IBS diagnosis in clinical practice.
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TAB L E 4 Multivariate analysis evaluating independent factors associated with consulting a doctor for IBS
AOR (95% CI) P value
Increasing age 1.02 (1.01–1.05) 0.02
Female 0.77 (0.42–1.40) 0.39
White race 1.44 (0.61–3.42) 0.39
Marital status 0.99 (0.57–1.73) 0.97
Country
United States 1
Canda 0.83 (0.39–1.79) 0.64
United Kingdom 0.79 (0.38–1.66) 0.53
IBS subtype
IBS‐C 1
IBS‐D 1.24 (0.58–2.66) 0.58
IBS‐M 1.55 (0.75–3.22) 0.24
IBS‐U 0.47 (0.13–1.72) 0.25
Health insurance status
Having health care insurance or access to free public health care 4.49 (1.31–15.44) 0.02
Most bothersome symptom
Abdominal pain 1
Watery/mushy stools 1.26 (0.59–2.67) 0.55
Hard stools 1.46 (0.65–3.29) 0.37
Abdominal bloating 0.80 (0.36–1.78) 0.59
None of the above 1.59 (0.38–6.62) 0.53
GI symptom frequency
Abdominal pain >3 times/week 1.17 (0.64–2.14) 0.61
Abdominal bloating >3 times/month 2.65 (1.42–4.93) <0.01
Non‐GI symptom burden
Non‐GI symptom burden 1.04 (0.97–1.12) 0.27
SF‐8 mental component score 1.02 (0.99–1.05) 0.08
Note: Significant differences in bold.
Abbreviations: AOR, adjusted odds ratios; CI, confidence interval; GI, gastrointestinal; IBS, irritable bowel syndrome.
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